Veru Enrolls First Patient in Phase 2 Clinical Trial of VERU-100, Novel Long-acting GnRH Antagonist Decapeptide Injection Formulation, for the Treatment of Hormone Sensitive Advanced Prostate Cancer

Joey Cohen
Medication Adherence

Matthew Durham
Omnidynamic Marketing

Daniel Sontupe
Market Access

Paul Theisen
Patient Acquisition

Pat Purcell
Meeting Engagement

Matt Turner
Patient Affordability

Stacey Gandler
Brand Nourishment

Suma Ramadas, PhD
Medical Affairs

Brenda Snow
Authentic Patient Voice

Frank Burrell
Scientific Storytelling

Amy Giles
Increasing Engagement

Liz Kane
Impactful Strategy

David Linetsky
Point-of-Care Marketing

Bud Bilanich
Success Coach